Promise Pharmacy, LLC, Palm Harbor, FL
Is Promise Pharmacy, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Promise Pharmacy, LLC hold a Florida pharmacy license?
The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH22007 for PROMISE PHARMACY, LLC, PALM HARBOR, status Clear and PH29090 for PROMISE PHARMACY LLC (dba Promise Pharmacy LLC), PALM HARBOR, status Clear. The Colorado State Board of Pharmacy also lists nonresident license OSP 6869 for Promise Pharmacy, Palm Harbor, FL, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054020703 for PROMISE PHARMACY LLC, PALM HARBOR, FL, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003425 for PROMISE PHARMACY, PALM HARBOR, FL, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0002134 for Promise Pharmacy, LLC, PALM HARBOR, FL, status Active, license A9-0001945 for Promise Pharmacy, LLC, Palm Harbor, FL, status Closed and license A9-0012869 for Promise Pharmacy, LLC, PALM HARBOR, FL, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301013512 for Promise Pharmacy, LLC, Palm Harbor, FL, status Active, as of Nov 10, 2026.
Has Promise Pharmacy, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jul 29, 2019), 1 warning letter close-out (Jul 27, 2022), 1 state referral letter (Jul 27, 2022) and 1 FMD-145 letter (Jul 27, 2022) for Promise Pharmacy, LLC. State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 2 actions: “Obligation(s) Satisfied” dated Sep 22, 2020, case 201806234 on license PH29090 and “Administrative Complaint Filed” dated May 21, 2020, case 201806234 on license PH29090. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Promise Pharmacy, LLC
- Location
- Palm Harbor, FL
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jul 27, 2022
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 16 observations
- State board records
- License found: PH22007, Clear; PH29090, Clear
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Promise Pharmacy, LLC, a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Jul 27, 2022 | State referral letter | Referral Letter to the Florida Board of Pharmacy Issued 07/27/2022 | FDA copy (archived) |
| Jul 27, 2022 | FMD-145 letter | FMD-145 Letter Issued 07/27/2022 | Not linked by FDA |
| Jul 27, 2022 | Warning letter close-out | Warning Letter Close Out Issued 07/27/2022 | Not linked by FDA |
| Sep 23, 2021 | Form 483 | 483 Issued 09/23/2021 | FDA copy (archived) |
| Jul 29, 2019 | Warning letter | Warning Letter (07/29/2019) | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Promise Pharmacy, LLC, Palm Harbor, FL (FEI number 3013207472), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 23, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013207472 | 1153148 |
| Oct 25, 2018 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013207472 | 1069714 |
Form 483s FDA has published for this site
- Sep 23, 2021: Form 483 to Promise Pharmacy, LLC, published Dec 17, 2021. fda.gov
- Nov 12, 2018: Form 483 to Promise Pharmacy, LLC, published Apr 30, 2019. fda.gov
- Oct 25, 2018: Form 483 to Promise Pharmacy, LLC, published May 13, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 16 numbered observations in all, across 2 inspections ending Oct 25, 2018 to Oct 25, 2018. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Oct 15, 2018 to Oct 25, 2018: 8 observations
- Firm on the cover
- Promise Pharmacy, LLC, 31318 Us Highway 19 N, Palm Harbor, FL 34684 -3713
- FEI number
- 3013207472
- Establishment type on the cover
- Producer of sterile and non-sterile products
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not.
Specifically, on 10/19/18, I observed the following:
An operator blocked first pass HEPA filtered air dming the production of Bremelanotide, Lot 1019018@4, BUD 12/18/18. •
An operator did not move slow and deliberate in the ISO 5 environment when transf ening partiallystoooered vials of Bremelanotide, Lot 1019018@4, BUD 12/18/18, from the compounding table to <Redacted B4>
f
An operator did not wear· a bear·d cover dming the production of HCG 2000ill Injectable, Lot10192018@6, BUD 04/17/18.
Observation 2
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Specifically, yom firm does not perform a visual examination of finished drug products prior to dispensing and distribution. On 10/16/18, I observed the presence of particulates in multiple bottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2, BUD 12/03/18. <Redacted B4> bottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2 had ah-eady been dispensed and distiibuted.
AM ENDMENT 1
Observation 3
The flow of components, drug product containers, closures and in-process materials though the building is not designed to prevent contamination.
Specifically,
A. The environment in which sterile, non-hazardous drug products are produced does not meet the standards of an ISO 5 environment due to the following:
HEP A filters do not cover the entire room. • • • •
There is no full assessment of the room's pressure differentials .
Smoke studies were not performed throughout the entire room .
There is a non-classified <Redacted B4> from the ISO 8 Prep room to the ISO 5 sterile environment.
B. On 10/19/18, I observed the transfer of partially stoppered Brenelanotide, Lot 10192018@4 from the stainless-steel compounding table to the <Redacted B4> in the ISO 5 sterile, non-hazardous room. I observed the <Redacted B4> is partially located under a light fixture that does not have a HEPA filter.
Observation 4
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
AM ENDMENT 1
Specifically, your fnm dof _n~t pe1form sterility and endotoxin testing on batches of sterile hazardous and non4hazardous dmg products o >< ~ials/bottles or less. Examples include, but are not limited to:
Ascorbic Acid Injection 450mg/mL Injectable, Lot 07202018@19, BUD 09/03/18
Arginine HCL 200mg/mL Injectable, Lot 02082018@13, BUD 03/25/18
Magnesium Sulfate 500mg/mL Injectable, Lot 08282018@2, BUD 10/12/18
Observation 5
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically,
A. Your firm does not perform potency testing on all batches of sterile drug products prior to release and distribution. Examples include, but are not limited to:
Ascorbic Acid 450mg/mL Injectable, Lot 07062018@2, BUD 08/20/18
Magnesium Sulfate 500mg/mL, Lot 08282018@2, BUD 10/12/18
Dexpanthenol USP 250mg/mL, Lot 02082018@15, BUD 03/25/18
Sermorelin GHRP 6 GHRP 2 PF 6mg/3mg/3mg Injectable, Lot 08302018@13, BUD 02/26/19
B. Your fnm released and distributed <Redacted B4> vials of Bremelanotide (PT141) 20mg Injectable Lot 05312018@4, BUD 07/30/18, with super-potent results for Bremelanotide of 114.3% (specification <Redacted B4>.
C. Your firm released and distiibuted vials of Sermorelin GHRP 6 GHRP 2 PF 6mg/3mg/3mg Injectable, Lot 05312018@3, BUD 11/27/18, with super-potent results for GHRP-2 of 112.4% (specifications 90-110%) and GHRP-6 of 113.8% GHRP-6 (specifications[(t>) (Ll-) I
4 D. ...
Observation 6
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, your firm lacks written procedures for a continuous stability program; and your firm does not perform stability testing for sterility or endotoxin on sterile hazardous and non-hazardous diug products. For example, Stability/BUD study for Ascorbic Acid 450mg/mL Injectable, Lot 05012018@42 to extend the BUD from 45 days to 90 days did not have sterility or endotoxin testing at the final test time point dated 07/27/18.
Observation 7
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, the validation of your fnm's <Redacted B4> and <Redacted B4> lack temperature mapping to ensure the required internal temperatures are reached and maintained throughout batch for the required runtime.
Observation 8
Your firm released drug produt in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.
Specifically,
AM ENDMENT1
A. Quality Related Event Report (QRE) dated 06/26/18: A complaint was received for Rx# <Redacted B6> for particles floating in the injectable a few days after reconstitution for AOD 9604 PF 6mg Injection, Lot 06182018@3, BUD 09/16/18. Your firm performed an investigation confnming the presence of particles for multiple lots of AOD 9604 PF 6mg Injection. The probable root cause was identified as a problem with the AOD powder, Lot <Redacted B4> used to produce the batches. Your firm failed to perform a risk assessment assessing the impact and to take correction actions, if indicated, regarding the following AOD injectable batches using AOD powder, Lot <Redacted B4> that were released and distributed 01162018@14, 03192018@2, 05142018@4, and 06182018@3
B. QRE dated 02/09/18: On 02/09/18, your firm identified a sterility failure for Thymosin B4 PF 15MG Injectable, Lot 01312018@1, BUD 05/01/18. ...
Inspection Oct 15, 2018 to Oct 25, 2018: 8 observations
- Firm on the cover
- Promise Pharmacy, LLC, 31818 us Highway 19 N, Palm Harbor, FL 34684 -3713
- FEI number
- 3013207472
- Establishment type on the cover
- Producer of sterile and non-sterile products
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drng products purporting to be sterile are not.
Specifically, on 10/19/18, I observed the following:
An operator blocked first pass HEP A filtered air during the production of Bremelanotide, Lot 1019018@4, BUD 12/18/18.
An operator did not move slow and deliberate in the ISO 5 environment when transfening partially stopped vials of Bremelanotide, Lot 1019018@4, BUD 12/18/18, from the compounding table to <Redacted B4>
An operator did not wear a beard cover during the production of HCG 2000TIJ Injectable, Lot 10192018@6, BUD 04/17/18.
Observation 2
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Specifically, your firm does not perform a visual examination of fmished drug products prior to dispensing and distiibution. On 10/16/18, I observed the presence of particulates in multiple bottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2, BUD 12/03/ 18.fl ibottles of Prednisolone and Gatifloxacin Ophthalmic Solution, Lot 09042018@2 had already been dispensed and distiibuted.
Observation 3
The flow of components, drug product containers, closures and in-process materials though the building is not designed to prevent contamination.
Specifically,
A. The environment in which sterile, non-hazardous drug products are produced does not meet the standards of an ISO 5 enviromnent due to the following:
HEPA filters do not cover the entire room. • • • •
HEPA filters do not cover the entire room. There is no full asessment of the room's pressure differentials. Smoke studies were not performed throughout the entire room .
There is a non-classified <Redacted B4> from the ISO 8 Prep room to the ISO 5 sterile environment.
B. On 10/18/18, I observed the transfer of partially stoppered Bremelanotide, Lot 10192018@4, from the stainless-steel compounding table to the <Redacted B4> in the ISO 5 stelile, non-hazardous room. I observed the <Redacted B4> is partially located under a light fixture that does not have a HEPA filter.
Observation 4
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
Ascorbic Acid Injection 450mg/mL Injectable, Lot 07202018@19, BUD 09/03/18
Arginine HCL 200mg/mL Injectable, Lot 02082018@13, BUD 03/25/18
Magnesium Sulfate 500mg/mL Injectable, Lot 08282018@2, BUD 10/12/18
Observation 5
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically,
A. Your firm does not perform potency testing on all batches of sterile drug products prior to release and distribution . Examples include, but are not limited to:
Ascorbic Acid 450mg/mL Injectable, Lot 07062018@2, BUD 08/20/18
Magnesium Sulfate 500mg/mL, Lot 08282018@2, BUD 10/12/18
Dexpanthenol USP 250mg/mL, Lot 02082018@15, BUD 03/25/18
Semorelin GHRP 6 GHRP 2 PF 6mg/3mg/3mg Injectable, Lot 08302018@13, BUD 02/26/19
B. Your firm released and distributed <Redacted B4> vials of Bremelanotide (PTl41) 20mg Injectable, Lot 05312018@4, BUD 07/30/18, with super-potent results for Bremelanotide of 114.3% (specifications <Redacted B4>
C. Your firm released and distiibuted <Reda cte d B4> vials of S en norel in GH RP 6 GHRP 2 PF 6mg/3mg/3 mg I njectable, L ot 0 5312018@3, BUD 11/27/18, wit h super- pote nt resu lts for GH RP-2 of 112.4% (sp ec i fi cations <Redacted B4> , land GHRP-6 of 113.8% GH R P -6 (specifications <Redacted B4>
D. ...
Observation 6
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, your finn lacks written procedures for a continuous stability program; and your film does not perfonn stability testing for sterility or endotoxin on sterile hazardous and non-hazardous drng products. For example, Stability/BUD study for Ascorbic Acid 450mg/mL Injectable, Lot 05012018@42 to extend the BUD from 45 days to 90 days did not have stetility or endotoxin testing at the final test time point dated 07/27/18.
Observation 7
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, the validation of your firm's <Redacted B4> and <Redacted B4> lack temperature mapping to ensure the required internal temperatures are reached and maintained throughout batch for the required runtime.
Observation 8
Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.
Specifically,
A. Quality Related Event Rep01t (QRE) dated 06/26/1 8: A complaint was received for Rx# <Redacted B4> for particles floating in the injectable a few days after reconstitution for AOD 9604 PF 6mg Injection, Lot 06182018@3, BUD 09/16/18. Your firm performed an investigation confirming the presence of particles for multiple lots of AOD 9604 PF 6mg Injection. The probable root cause was identified as a problem with the AOD powder, Lot <Redacted B4> used to produce the batches. Your firm failed to perform a risk assessment assessing the impact and to take corrective actions, if indicated, regarding the following AOD injectable batches using AOD powder, Lot <Redacted B4> , lthat were released and distributed: 01162018@14, 03192018@2, 05142018@4, and 06182018@3.QRE dated 02/09/18.
B. On 02/09/18, your firm identified a sterility failure for Thymosin B4 PF l 5MG Injectable, Lot 01312018@1, BUD 05/01/18. ...
Linked 483s whose text is not shown
- Sep 23, 2021: FDA document 154890: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH22007 | Pharmacy | PROMISE PHARMACY, LLC | PALM HARBOR | Clear |
| PH29090 | Pharmacy | PROMISE PHARMACY LLC (dba Promise Pharmacy LLC) | PALM HARBOR | Clear |
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Sep 22, 2020: “Obligation(s) Satisfied”, license PH29090, case 201806234, PROMISE PHARMACY LLC, PALM HARBOR, FL. Board list
- May 21, 2020: “Administrative Complaint Filed”, license PH29090, case 201806234, PROMISE PHARMACY LLC, PALM HARBOR, FL. Board list
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 6869 | OSP | Promise Pharmacy | Palm Harbor, FL | Active |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054020703 | LICENSED PHARMACY | PROMISE PHARMACY LLC | PALM HARBOR, FL | ACTIVE |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0003425 | NONRESIDENT PHARMACY | PROMISE PHARMACY | PALM HARBOR, FL | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0002134 | Non Resident Pharmacy | Promise Pharmacy, LLC | PALM HARBOR, FL | Active |
| A9-0001945 | Non Resident Pharmacy | Promise Pharmacy, LLC | Palm Harbor, FL | Closed |
| A9-0012869 | Non Resident Pharmacy | Promise Pharmacy, LLC | PALM HARBOR, FL | Closed |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301013512 | Pharmacy | Promise Pharmacy, LLC | Palm Harbor, FL | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Florida Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.